FONT-SIZE Plus   Neg

VIVUS Says FDA Extends Qnexa PDUFA Date

VIVUS Inc. (VVUS) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the Qnexa New Drug Application by three months from April 17 to July 17, 2012.

On April 4, following the FDA's request, VIVUS submitted the Qnexa Risk Evaluation and Mitigation Strategy, which was considered a major amendment to the NDA. The submission consisted of proposed REMS materials.

Since the receipt date was within three months of the user fee goal date, the FDA is extending the Prescription Drug User Fee Act date by three months to provide time for a full review of the submission, the company noted.

The Qnexa NDA seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Germany's Deutsche Bank AG reported Thursday a profit in its third quarter, compared to loss a year ago. Last year, the company had registered a hefty 5.8 billion euros impairment charge related to Hua Xia Bank Co. Revenues also were higher in the quarter. Shares of Nokia Corp. were losing around 8 percent in the early morning trading after the Finnish network equipment maker reported a loss in its third quarter, compared to a profit last year. The results reflected costs related to Alcatel-Lucent deal. The company also said its Chief Financial Officer Timo Ihamuotila resigned to join Swiss engineering firm ABB Ltd. as CFO. Electric car maker Tesla Motors Inc. (TSLA), Wednesday reported a profit for the third quarter beating Wall Street estimates by a large margin, driven primarily by record production and deliveries. Shares of the company gained over 5 percent in extended hours after the company reaffirmed its delivery...
comments powered by Disqus
Follow RTT